[]

Find Clinical Drug Pipeline Developments & Deals for 9041-93-4

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Children's Oncology Group

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Children's Oncology Group

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 01, 2017

                          Lead Product(s) : Bleomycin Sulphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Sydney

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          University of Sydney

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Bleomycin Sulphate

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Cambridge University Hospitals NHS Foundation Trust | Cancer Trials Ireland | Children's Oncology Group | Dana-Farber Cancer Institute | University of Southern California

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 21, 2015

                          Lead Product(s) : Bleomycin Sulphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Cambridge University Hospitals NHS Foundation Trust | Cancer Trials Ireland | Children's Oncology Group | Dana-Farber Cancer Institute | University of Southern California

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank